patient subgroup...
subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
chloroquine and derivatives - versus potential COVID-19 treatments - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 1.12 [0.99, 1.27]< 1 33% 5 studies (4/1) 3.2 % serious not evaluable low crucial - deaths 0.84 [0.70, 1.01]< 1 77% 42 studies (28/14) 96.5 % moderate low moderate crucial - deaths (time to event analysis only) 0.85 [0.64, 1.13]< 1 92% 10 studies (3/7) 87.4 % serious low low crucial - clinical deterioration 1.05 [0.87, 1.26]< 1 0% 8 studies (5/3) 30.0 % serious not evaluable low important - clinical improvement 1.07 [0.83, 1.39]> 1 0% 3 studies (3/-) 69.8 % some concern not evaluable moderate important - clinical improvement (14-day) 1.01 [0.78, 1.30]> 1 0% 4 studies (4/-) 52.1 % low not evaluable high important - clinical improvement (28-day) 0.97 [0.69, 1.37]> 1 0% 1 study (1/-) 43.2 % NA not evaluable important - clinical improvement (7-day) 1.16 [0.84, 1.61]> 1 0% 1 study (1/-) 81.4 % NA not evaluable important - clinical improvement (time to event analysis only) 0.96 [0.81, 1.14]> 1 0% 5 studies (4/1) 32.9 % moderate not evaluable moderate important - death or ventilation 1.12 [1.02, 1.22]< 1 0% 6 studies (5/1) 0.6 % moderate not evaluable moderate important - hospital discharge 1.13 [0.88, 1.45]> 1 39% 6 studies (5/1) 82.2 % moderate not evaluable moderate important - mechanical ventilation 0.98 [0.64, 1.49]< 1 0% 1 study (-/1) 54.5 % NA not evaluable important - mechanical ventilation (time to event analysis only) 1.43 [0.53, 3.82]< 1 0% 1 study (-/1) 23.8 % NA not evaluable important - radiologic improvement (14-day) 1.33 [0.94, 1.88]> 1 0% 1 study (1/-) 94.7 % NA not evaluable important - radiologic improvement (7-day) 3.19 [1.16, 8.79]> 1 0% 2 studies (2/-) 98.7 % high not evaluable low important - viral clearance 1.35 [0.77, 2.38]> 1 68% 5 studies (4/1) 85.1 % moderate not evaluable moderate important - viral clearance (time to event analysis only) 1.00 [0.73, 1.38]> 1 20% 3 studies (1/2) 51.1 % serious not evaluable low important - viral clearance by day 14 1.63 [0.62, 4.28]> 1 84% 4 studies (2/2) 83.7 % serious not evaluable low important - viral clearance by day 7 1.20 [0.60, 2.40]> 1 0% 1 study (1/-) 69.7 % NA not evaluable important - ICU admission 1.19 [0.72, 1.96]< 1 4% 2 studies (2/-) 24.6 % some concern not evaluable moderate non important - off oxygenation 0.98 [0.64, 1.51]> 1 0% 1 study (1/-) 46.4 % NA not evaluable non important - 00 cardiac arrest 1.91 [1.01, 3.62]< 1 0% 2 studies (1/1) 2.3 % serious not evaluable low important - serious adverse events 1.26 [0.56, 2.84]< 1 0% 1 study (1/-) 28.7 % NA not evaluable important - abnormal ECG findings 1.50 [0.88, 2.57]< 1 0% 1 study (-/1) 7.0 % NA not evaluable non important - adverse events 1.57 [1.15, 2.15]< 1 20% 9 studies (9/-) 0.2 % some concern not evaluable moderate non important - arrhythmia 1.05 [0.57, 1.94]< 1 0% 1 study (-/1) 43.4 % NA not evaluable non important -
LoD: level of statistical demonstration:
